Migraine boost
PHARMACEUTICALS group Vernalis’s annual pre-tax loss narrowed to £2.8million from £11.3million last time helped by royalties from its flagship migraine drug Frovatriptan.
Group revenues rose to £14.2million from £13million. Its shares jumped 4½p to 43½p.